Potent metabotropic glutamate mGlu1
receptor antagonist (IC50
= 6.3 μ
M at rat mGlu1a
). Displays ≥ 40-fold selectivity over other receptors: mGlu5
> 300 μ
M), NMDA and AMPA (IC50
= 250 μ
M). Neuroprotective in cultured murine cortical cells and rat hippocampal slice cultures in vitro
. Reduces the volume of ischemia-induced brain infarcts in rats following systemic administration in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death.
Moroni et al.
Metabotropic glutamate 1 (mGlu1) receptor antagonists enhance GABAergic neurotransmission: a mechanism for the attenuation of post-ischemic injury and epileptiform activity?
Cozzi et al.
Stereoselective synthesis and preliminary evaluation of (+)- and (-)-3-methyl-5-carboxy-thien-2-yl-glycine (3-MATIDA): identification of (+)-3-MATIDA as a novel mGluR1 competitive antagonist.
Constantino et al.
Il Farmaco, 2004;59:93